These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35859133)

  • 21. Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
    Luo Y; Wang Y; Shu Y; Lu Q; Xiao R
    Int J Biochem Cell Biol; 2015 Oct; 67():92-100. PubMed ID: 26043891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A methodology for exploring biomarker--phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations.
    Huang H; Fava A; Guhr T; Cimbro R; Rosen A; Boin F; Ellis H
    BMC Bioinformatics; 2015 Sep; 16():293. PubMed ID: 26373409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma.
    Zhu H; Luo H; Zuo X
    Exp Mol Med; 2013 Sep; 45(9):e41. PubMed ID: 24052166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint).
    Herrick AL; Shukla R; Watson REB
    Exp Dermatol; 2020 Dec; 29(12):1144-1153. PubMed ID: 32840924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
    Jaeger VK; Wirz EG; Allanore Y; Rossbach P; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Balbir Gurman A; Tikly M; Vettori S; Damjanov N; Müller-Ladner U; Distler JH; Li M; Walker UA;
    PLoS One; 2016; 11(10):e0163894. PubMed ID: 27706206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Imaging Strategies in Systemic Sclerosis.
    Wolf M; Montesi SB
    Curr Rheumatol Rep; 2020 Aug; 22(9):57. PubMed ID: 32785794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lung impairment in systemic sclerosis].
    Knoop H; Arinir U; Kreuter A; Walther JW; Schultze-Werninghaus G; Rohde G
    Pneumologie; 2009 Sep; 63(9):497-507. PubMed ID: 19708006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of progression in systemic sclerosis patients with interstitial lung disease.
    Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis.
    Weigold F; Günther J; Pfeiffenberger M; Cabral-Marques O; Siegert E; Dragun D; Philippe A; Regensburger AK; Recke A; Yu X; Petersen F; Catar R; Biesen R; Hiepe F; Burmester GR; Heidecke H; Riemekasten G
    Arthritis Res Ther; 2018 Mar; 20(1):52. PubMed ID: 29566745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis.
    Yayla ME; İlgen U; Okatan İE; UsluYurteri E; Torgutalp M; Keleşoğlu Dinçer AB; Aydemir Gülöksüz EG; Sezer S; Turgay TM; Kınıklı G; Ateş A
    Clin Rheumatol; 2020 Jan; 39(1):77-83. PubMed ID: 31317426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.
    Nagaraja V; Matucci-Cerinic M; Furst DE; Kuwana M; Allanore Y; Denton CP; Raghu G; Mclaughlin V; Rao PS; Seibold JR; Pauling JD; Whitfield ML; Khanna D
    Arthritis Rheumatol; 2020 Jul; 72(7):1049-1058. PubMed ID: 32134199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review.
    Paxton D; Pauling JD
    Semin Arthritis Rheum; 2018 Dec; 48(3):482-494. PubMed ID: 29602558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatment options in systemic Sclerosis (Scleroderma).
    Stummvoll GH
    Acta Med Austriaca; 2002; 29(1):14-9. PubMed ID: 11899748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of alterations in X-linked IRAK1gene and miR-146a on susceptibility and clinical manifestations in patients with systemic sclerosis.
    Vreca M; Andjelkovic M; Tosic N; Zekovic A; Damjanov N; Pavlovic S; Spasovski V
    Immunol Lett; 2018 Dec; 204():1-8. PubMed ID: 30308218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
    Ghizzoni C; Sebastiani M; Manfredi A; Campomori F; Colaci M; Giuggioli D; Ferri C
    Microvasc Res; 2015 May; 99():92-5. PubMed ID: 25842153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.